Continuum Advisory’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
Other funds holding RXRX
AIM
MCMU
Continuum Advisory's RXRX Position: Q2 2026 in Review
Continuum Advisory opened a new position in Recursion Pharmaceuticals (RXRX) in Q2 2026: 61 shares worth $224. The stake represents ﹤0.01% of the portfolio and ranks #1951 among its holdings. This is a return to the name: Continuum Advisory previously reported a position in RXRX as recently as Q2 2024.
Continuum Advisory first reported a position in RXRX in Q1 2024 and has held it in 3 quarters since. The position peaked at $2.59K in Q1 2024. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.
- Continuum Advisory held 61 shares of Recursion Pharmaceuticals worth $224 as of Q2 2026.
- Recursion Pharmaceuticals was a new Continuum Advisory position in Q2 2026.
- Recursion Pharmaceuticals made up ﹤0.01% of Continuum Advisory's portfolio in Q2 2026, its #1951 holding.
- Continuum Advisory first reported a position in Recursion Pharmaceuticals in Q1 2024 and has held it in 3 quarters since.
- Continuum Advisory's Recursion Pharmaceuticals position peaked at $2.59K in Q1 2024.
- 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.
Based on Continuum Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.